{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:09:37Z","timestamp":1792642177544,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":3219,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1093\/annonc\/mdq609","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T04:14:32Z","timestamp":1287461672000},"page":"257-267","source":"Crossref","is-referenced-by-count":140,"title":["Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper"],"prefix":"10.1016","volume":"22","author":[{"given":"M.","family":"Aapro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bernard-Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.G.C.","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Batist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Erdkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Krzemieniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lluch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Monfardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ryberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Soubeyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Wedding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq609_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2007.14.8742","article-title":"Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?","volume":"26","author":"Ewer","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0015","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/annonc\/mdn728","article-title":"Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk","volume":"20","author":"Barrett-Lee","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8588(05)70274-4","article-title":"Cancer and aging. An evolving panorama","volume":"14","author":"Balducci","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1093\/annonc\/mdq609_bb0025","unstructured":"SEER Stat Fact Sheets: Breasthttp:\/\/seer.cancer.gov\/statfacts\/html\/breast.html (17 April 2009, date last accessed)"},{"key":"10.1093\/annonc\/mdq609_bb0030","unstructured":"SEER Stat Fact Sheets: Non-Hodgkin Lymphomahttp:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html (17 April 2009, date last accessed)"},{"key":"10.1093\/annonc\/mdq609_bb0035","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1200\/JCO.2003.04.002","article-title":"Aggressive treatment for the fit elderly with non-small cell lung cancer? Yes!","volume":"21","author":"Sequist","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0040","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq609_bb0045","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1200\/JCO.2007.10.6583","article-title":"International Society of Geriatric Oncology chemotherapy taskforce: evaluation of chemotherapy in older patients\u2014an analysis of the medical literature","volume":"25","author":"Lichtman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0050","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq609_bb0055","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mdq609_bb0060","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/cncr.23315","article-title":"Dying with cancer: the influence of age, comorbidity, and cancer site","volume":"112","author":"Kendal","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq609_bb0065","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.2008.16.5274","article-title":"Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities","volume":"26","author":"Carver","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0070","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdm563","article-title":"Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome","volume":"19","author":"Thieblemont","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0075","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.critrevonc.2003.04.004","article-title":"Understanding and preventing drug interactions in elderly patients","volume":"48","author":"Delafuente","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdq609_bb0080","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1200\/JCO.2003.02.046","article-title":"Undertreatment strongly decreases prognosis of breast cancer in elderly women","volume":"21","author":"Bouchardy","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0085","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ejca.2008.11.028","article-title":"The cancer survival gap between elderly and middle-aged patients in Europe is widening","volume":"45","author":"Quaglia","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdq609_bb0090","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1200\/JCO.2003.12.019","article-title":"The outcome of combined-modality therapy for stage III non-small-cell-lung cancer in the elderly","volume":"21","author":"Schild","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0095","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/107327480701400106","article-title":"Tolerance to chemotherapy in elderly patients with cancer","volume":"14","author":"Wedding","year":"2007","journal-title":"Cancer Control"},{"key":"10.1093\/annonc\/mdq609_bb0100","author":"Philips","year":"2010","journal-title":"Oxford Center for Evidence-based Medicine levels of evidence"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdq609_bb0105","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.3747\/co.2008.173","article-title":"Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer","volume":"15","author":"Towns","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0110","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdq609_bb0115","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJM200506093522321","article-title":"Acute doxorubicin cardiotoxicity","volume":"352","author":"Hayek","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq609_bb0120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/europace\/eum033","article-title":"Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator","volume":"9","author":"Rudzinski","year":"2007","journal-title":"Europace"},{"key":"10.1093\/annonc\/mdq609_bb0125","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","article-title":"Cardiac toxicity 4 to 20 years after completing anthracycline therapy","volume":"266","author":"Steinherz","year":"1991","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdq609_bb0130","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1200\/JCO.2007.14.9401","article-title":"Anthracycline cardiotoxicity: from bench to bedside","volume":"2","author":"Gianni","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0135","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq609_bb0140","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq609_bb0145","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq609_bb0150","article-title":"Left ventricular function following adjuvant chemotherapy for breast cancer: the NCI CTG MA.5 experience","volume":"24","author":"Shepherd","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0155","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1470-2045(09)70042-7","article-title":"Cardiovascular toxicity caused by cancer treatment: strategies for early detection","volume":"10","author":"Altena","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0160","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00520-007-0397-6","article-title":"Detection and monitoring of cardiotoxicity\u2014what does modern cardiology offer?","volume":"16","author":"Jurcut","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdq609_bb0165","first-page":"160","article-title":"Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines","volume":"30","author":"Pudil","year":"2008","journal-title":"Exp Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0170","first-page":"309","article-title":"Asssessment of anthracycline induced cardiotoxicity with biochemical markers","volume":"29","author":"Horacek","year":"2007","journal-title":"Exp Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0175","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00392-007-0633-6","article-title":"Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults","volume":"97","author":"Dodos","year":"2008","journal-title":"Clin Res Cardiol"},{"key":"10.1093\/annonc\/mdq609_bb0180","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/07357900009012191","article-title":"A prospective pharmacological evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer","volume":"18","author":"Dees","year":"2000","journal-title":"Cancer Invest"},{"key":"10.1093\/annonc\/mdq609_bb0185","first-page":"4467","article-title":"Age dependence of the early phase-pharmacokinetics of doxorubicin","volume":"43","author":"Robert","year":"1983","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdq609_bb0190","article-title":"Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy","volume":"4","author":"Van Dalen","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdq609_bb0195","article-title":"Different anthracycline derivates for reducing cardiotoxicity in cancer patients","volume":"4","author":"Van Dalen","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdq609_bb0200","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/annonc\/mdj034","article-title":"Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results","volume":"17","author":"Fumoleau","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0205","doi-asserted-by":"crossref","first-page":"vi66","DOI":"10.1093\/annonc\/mdm228","article-title":"Liposomal-encapsulated doxorubicin plus cyclophosphamide as first line therapy in metastatic breast cancer: a phase II multicentric study","volume":"18","author":"Giotta","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0210","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/cncr.20207","article-title":"Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?","volume":"100","author":"Theodoulou","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdq609_bb0215","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0220","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: use of chemotherapy and radiotherapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003917.pub3","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","volume":"2","author":"Van Dalen","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdq609_bb0230","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1093\/annonc\/mdq609_bb0235","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1093\/annonc\/mdq609_bb0240","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0245","author":"Peto","year":"2007","journal-title":"The worldwide overview: new results for systemic adjuvant therapies. San Antonio Breast Cancer Symposium"},{"key":"10.1093\/annonc\/mdq609_bb0250","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa050518","article-title":"Effects of screening and adjuvant therapy on mortality from breast cancer","volume":"353","author":"Berry","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq609_bb0255","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq609_bb0260","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.critrevonc.2007.12.008","article-title":"A significant proportion of elderly patients develop hormone-dependent \u201cluminal B\u201d tumours associated with aggressive characteristics","volume":"67","author":"Durbecq","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdq609_bb0265","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1200\/JCO.2005.03.6053","article-title":"Adjuvant chemotherapy and survival in elderly women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort","volume":"24","author":"Elkin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0270","first-page":"286","article-title":"Adjuvant treatment of breast cancer in the elderly","volume":"22","author":"Downey","year":"2008","journal-title":"Oncology (Williston Park)"},{"key":"10.1093\/annonc\/mdq609_bb0275","first-page":"1","article-title":"United States life tables, 2002","volume":"53","author":"Arias","year":"2004","journal-title":"Natl Vital Stat Rep"},{"key":"10.1093\/annonc\/mdq609_bb0280","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","article-title":"Annual hazard rates of recurrence for breast cancer after primary therapy","volume":"14","author":"Saphner","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0285","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1200\/JCO.2004.02.145","article-title":"Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6 year follow-up results of the French adjuvant study group 08 trial","volume":"22","author":"Fargeot","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0290","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa0810266","article-title":"Adjuvant chemotherapy in older women with early-stage breast cancer","volume":"360","author":"Muss","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mdq609_bb0295","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","article-title":"Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735","volume":"27","author":"Jones","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0300","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1023\/A:1008315312795","article-title":"Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up","volume":"11","author":"Ibrahim","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0305","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0310","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/annonc\/mdn292","article-title":"Anthracycline-trastuzumab regimens for HER2\/neu-overexpressing breast cancer: current experience and future strategies","volume":"19","author":"Rayson","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0315","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"36","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq609_bb0320","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3747\/co.2008.199","article-title":"Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group","volume":"15","author":"Mackey","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0325","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0330","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatanib: pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1093\/annonc\/mdq609_bb0335","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatanib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq609_bb0340","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq609_bb0345","first-page":"26","article-title":"Randomized, double-blind, placebo-controlled phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer: AVADO","author":"Miles","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0350","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1345\/aph.1L426","article-title":"Intricacies of bevacizumab-induced toxicities and their management","volume":"3","author":"Gressett","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1093\/annonc\/mdq609_bb0355","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/jnci\/djn206","article-title":"New insights into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients","volume":"100","author":"Ryberg","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdq609_bb0360","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.7-suppl_6-4","article-title":"Treatment for anthracycline-pretreated metastatic breast cancer","volume":"7","author":"O'Shaughnessy","year":"2002","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdq609_bb0365","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq609_bb0370","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0375","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/annonc\/mdh393","article-title":"Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer","volume":"15","author":"Chan","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0380","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ejca.2005.12.011","article-title":"A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)","volume":"42","author":"Coleman","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdq609_bb0385","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.critrevonc.2006.07.008","article-title":"A joined analysis of two EORTC studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer","volume":"61","author":"Biganzoli","year":"2007","journal-title":"Clin Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdq609_bb0390","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2006.10.5957","article-title":"Lymphoma in older patients","volume":"25","author":"Thieblemont","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0395","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev.med.59.060906.220345","article-title":"A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma","volume":"59","author":"Molina","year":"2008","journal-title":"Ann Rev Med"},{"key":"10.1093\/annonc\/mdq609_bb0400","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0405","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1182\/blood-2002-10-3238","article-title":"CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment","volume":"101","author":"Osby","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq609_bb0410","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1995.13.10.2530","article-title":"Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy","volume":"13","author":"Sonneveld","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0415","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1200\/JCO.1998.16.1.27","article-title":"CHOP is the standard regimen in patients > or = 70 years of age with intermediate-and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group","volume":"16","author":"Tirelli","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0420","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults","volume":"22","author":"Hequet","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0425","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0430","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hon.827","article-title":"Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac disease or pre-treated with anthracyclines","volume":"25","author":"Rigacci","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0435","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/10428190802043853","article-title":"R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin's lymphoma: a pilot study","volume":"49","author":"Visani","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdq609_bb0440","first-page":"2596","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with follicular, indolent and mantle-cell lymphomas: results of a randomized phase III study of the Study Group Indolent Lymphomas","volume":"112","author":"Rummel","year":"2008","journal-title":"Proc Am Soc Hematol; Blood"},{"key":"10.1093\/annonc\/mdq609_bb0445","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0450","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq609_bb0455","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1634\/theoncologist.2008-0112","article-title":"Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer","volume":"13","author":"Lenihan","year":"2008","journal-title":"Oncologist"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419386764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419386764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/2\/257\/409663\/mdq609.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:55:12Z","timestamp":1624438512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419386764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0923753419386764"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq609","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}